Similar Items: Studying When to Add Biological Therapy to Cytotoxic Therapy in Advanced Cancer Care Using Real World Data: How to Avoid Design Choices That Generate Immortal Time
- Antidiabetic agents as potential cytotoxic candidates for cancer therapy
- Jianpi Rougan Method in Support of Lenvatinib Therapy: A Real-World Study on Maintaining Relative Dose Intensity and Mitigating Toxicity–Driven Discontinuation in Intermediate-to-Advanced HCC
- Advances in Phase III Clinical Trials and Future Challenges of Targeted Therapy in Advanced Ovarian Cancer
- Intelligent nano‐platforms in breast cancer therapy: Current advances and future perspectives
- Safety and Tolerability of Different Total Neoadjuvant Therapies in Patients With Locally Advanced Rectal Cancer
- Editorial: 3rd international workshop on microdosimetry for particle therapy: Bridging physics and biology